Vaccine 2021 05 6;39(19):2605-2607. Epub 2021 Apr 6.
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address:
Engineering (Beijing) 2021 May 3. Epub 2021 May 3.
Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Given the scarcity of safe and effective COVID-19 vaccines, a chief policy question is how to allocate them among different sociodemographic groups. This paper evaluates COVID-19 vaccine prioritization strategies proposed to date, focusing on their stated goals; the mechanisms through which the selected allocations affect the course and burden of the pandemic; and the main epidemiological, economic, logistical, and political issues that arise when setting the prioritization strategy. The paper uses a simple, age-stratified susceptible-exposed-infectious-recovered model to quantitatively assess the performance of alternative prioritization strategies with respect to avoided deaths, avoided infections, and life-years gained. Read More
Cleve Clin J Med 2021 May 9. Epub 2021 May 9.
Research Fellow, Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
Attaining equity in vaccination distribution is a moral and ethical goal that ensures all members of our community are properly cared for. We suggest a comprehensive approach that involves allocating community resources based on local economic, demographic, and COVID-19 infection data, removing technology barriers by staffing vaccine appointment call-in centers, distributing vaccines based on objective factors (eg, household density) rather than on a "first come, first served" basis, and creating pop-up vaccination sites at trusted community organizations such as federally qualified healthcare centers, churches, libraries, and barber/beauty shops. Until every community is safe, no community will be safe. Read More
Hum Genomics 2021 05 10;15(1):27. Epub 2021 May 10.
Australian Institute of Tropical Health and Medicine, James Cook University, Smithfield, Queensland, 4878, Australia.
COVID-19 has engulfed the world and it will accompany us all for some time to come. Here, we review the current state at the milestone of 1 year into the pandemic, as declared by the WHO (World Health Organization). We review several aspects of the on-going pandemic, focusing first on two major topics: viral variants and the human genetic susceptibility to disease severity. Read More
Vaccine 2021 May 4. Epub 2021 May 4.
National Primary Health Care Development Agency, Abuja, Nigeria.
Background: The global polio eradication initiative has made giant stride by achieving a 99% reduction in Wild poliovirus (WPV) cases, with Nigeria on the verge of being declared polio-free following over 36 months without a WPV. The initiative has provided multiple resources, assets and lessons learnt that could be transitioned to other public health challenges, including improving the quality and vaccination coverage of measles campaigns in order to reduce the incidences of measles in Nigeria. We documented the polio legacy and assets used to support the national measles campaign in 2017/2018. Read More
Chin Med J (Engl) 2021 Apr 28. Epub 2021 Apr 28.
NHC Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu 210009, China; Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong 518057, China; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China; Beijing Minhai Biological Technology Co., Ltd., Beijing 102600, China; Huaiyin District Center for Disease Control and Prevention, Huaian, Jiangsu 223003, China; Vazyme Biotech Co., Ltd, Nanjing, Jiangsu 210000, China China National Institutes for Food and Drug Control, Beijing 102629, China; Center for Global Health, Nanjing Medical University, Nanjing, Jiangsu 211166,China.
Background: The significant morbidity and mortality resulted from the infection of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for urgent development of effective and safe vaccines. We report the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults.Methods: Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials of KCONVAC were conducted in healthy Chinese adults aged 18-59 years. Read More